secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001493152-24-010921
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports complete clinical response in 3 fusarium patients with oral MAT2203
--------------------------------------------------------------------------------

- Three patients with azole-resistant invasive fusarium infection achieved complete clinical response after oral MAT2203 treatment.
- Two of these patients had not yet achieved complete resolution at the time of the prior 19-patient update.
- Patients could not tolerate IV amphotericin B due to nephrotoxicity; oral MAT2203 resolved infections over 2 weeks to 6 months.
- Results bolster confidence for upcoming Phase 3 ORALTO trial in invasive aspergillosis with limited treatment options.
- MAT2203 is not yet licensed or approved anywhere globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224010921/0001493152-24-010921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224010921/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer